CytRx Corporation

Attention CytRx Corporation Investors: CytRx Misled Investors According to a Recently Filed Class Action

Robbins Arroyo LLP announces that an investor of CytRx Corporation (NASDAQ: CYTR) has filed a federal securities fraud class action complaint in the U.S. District Court for the Central District of California. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between November 22, 2013 and March 13, 2014, including the company’s public offering on February 5, 2014 (the “Class Period”). CytRx is a biopharmaceutical research and development company specializing in oncology.

CytRx Is Accused of Engaging in a Misleading Promotional Campaign

According to the complaint, shares of CytRx fell $0.56 per share, or 8.5%, to close at $6.04 on February 12, 2014, following the publication of an article on TheStreet.com claiming that CytRx retained an investor relations firm accused of using deceptive practices to tout its clients’ stock. Specifically, the complaint charges that an investor relations firm, the DreamTeamGroup, was hired by CytRx to tout the company and promote its stock. The complaint charges that the DreamTeamGroup misled investors by publishing favorable articles about its clients while falsely stating that the articles were written by authors who were not paid by the company. Then, on March 13, 2014, CytRx’s stock fell an additional $0.61 per share to close at $4.17, following the publication of an article on seekingalpha.com detailing the role of CytRx management in editing, and approving the paid for articles.

The complaint further alleges that CytRx’s stock traded at artificially high prices because of this misleading campaign, and that CytRx’s CEO, President and Director, Steven A. Kriegsman, sold $2.1 million of Galena Biopharma, Inc. shares while that stock was artificially inflated because of a similar promotion employing the DreamTeamGroup. Mr. Kriegsman has been a member of the Board of Directors at Galena since 2006.

CytRx Shareholders Are Encouraged to Contact Shareholder Rights Law Firm Robbins Arroyo

If you invested in CytRx and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003,or you can complete the form below and we will contact you directly.

 

Shareholder Information

 

Items marked with an asterisk (*) are required information.

Last Name *

CityState/Province *

Country/RegionPhone *

Confirm: E-mail *

Business Email

Number of Shares:Buy Date :Price Per Share:

example: 125example: MM/DD/YYYYexample: 30.00

If you have additional transactions or comments, please input the information below:

Number of Shares:Buy Date :Price Per Share:

example: 125example: MM/DD/YYYYexample: 30.00

If you have additional transactions or comments, please input the information below:

First Name *
Address ZIP/Postal Code E-mail *
Shares Purchased:
transaction: transaction: transaction: transaction: transaction:
Shares Sold:
transaction: transaction: transaction: transaction: transaction:
Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.
* I have read the disclaimer information
    Send This Post

    Tags: